Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK 1,421.50
+22.50 (1.61%)
May 2, 2025, 4:59 PM CET
Revenue by Product
Financial numbers in millions DKK.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Total Royalties | 17,352 |
Log In |
Log In |
Log In |
Log In |
| Total Royalties Growth | 26.61% |
Log In |
Log In |
Log In |
Log In |
| Reimbursement | 996 |
Log In |
Log In |
Log In |
Log In |
| Reimbursement Growth | 15.28% |
Log In |
Log In |
Log In |
Log In |
| Milestone | 1,000 |
Log In |
Log In |
Log In |
Log In |
| Milestone Growth | - |
Log In |
Log In |
Log In |
Log In |
| License | 2 |
Log In |
Log In |
Log In |
Log In |
| DARZALEX Royalties | 13,922 |
Log In |
Log In |
Log In |
Log In |
| DARZALEX Royalties Growth | 23.59% |
Log In |
Log In |
Log In |
Log In |
| Kesimpta Royalties | 2,222 |
Log In |
Log In |
Log In |
Log In |
| Kesimpta Royalties Growth | 48.73% |
Log In |
Log In |
Log In |
Log In |
| TEPEZZA Royalties | 737 |
Log In |
Log In |
Log In |
Log In |
| TEPEZZA Royalties Growth | 4.69% |
Log In |
Log In |
Log In |
Log In |
| Other Product Royalties | 471 |
Log In |
Log In |
Log In |
Log In |
| Other Product Royalties Growth | 94.63% |
Log In |
Log In |
Log In |
Log In |
| Collaboration | 433 |
Log In |
Log In |
Log In |
Log In |
| Collaboration Growth | 41.04% |
Log In |
Log In |
Log In |
Log In |
| Net Product Sales | 1,743 |
Log In |
Log In |
Log In |
Log In |
| Janssen | 14,422 |
Log In |
Log In |
Log In |
Log In |
| Janssen Growth | 20.70% |
Log In |
Log In |
Log In |
Log In |
| Novartis | 2,822 |
Log In |
Log In |
Log In |
Log In |
| Novartis Growth | 86.76% |
Log In |
Log In |
Log In |
Log In |
| BioNTech | 869 |
Log In |
Log In |
Log In |
Log In |
| BioNTech Growth | 10.84% |
Log In |
Log In |
Log In |
Log In |
| Pfizer | 533 |
Log In |
Log In |
Log In |
Log In |
| Pfizer Growth | 42.90% |
Log In |
Log In |
Log In |
Log In |
| Other Collaboration Partner | 2 |
Log In |
Log In |
Log In |
Log In |
| Other Collaboration Partner Growth | - |
Log In |
Log In |
Log In |
Log In |
| Roche | 741 |
Log In |
Log In |
Log In |
Log In |
| Roche Growth | 5.26% |
Log In |
Log In |
Log In |
Log In |
| AbbVie | 394 |
Log In |
Log In |
Log In |
Log In |
| AbbVie Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Financial numbers in millions DKK.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Denmark | 19,783 |
Log In |
Log In |
Log In |
Log In |
| Denmark Growth | - |
Log In |
Log In |
Log In |
Log In |
| United States | 902 |
Log In |
Log In |
Log In |
Log In |
| Japan | 841 |
Log In |
Log In |
Log In |
Log In |